1. A compound of Formula II,
or a physiologically acceptable salt thereof, wherein,
R5 is substituted or unsubstituted aralkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted cycloalkylalkyl;
R6 is \u2014H or \u2014NR13R14;
R7 is substituted or unsubstituted phenyl; and
R13 and R14 are each, independently, \u2014H, a substituted or unsubstituted alkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl; or
R13 and R14 together with the nitrogen to which they are attached are a heterocycloalkyl.
2. The compound of claim 1, wherein R5 is substituted or unsubstituted benzyl.
3. The compound of claim 2, wherein R5 is benzyl having one or more substituents independently selected from the group consisting of halogen, linear C1-C4-alkoxy and branched C1-C4-alkoxy.
4. The compound of claim 3, wherein R5 is benzyl having one or more substituents independently selected from the group consisting of chloro and methoxy.
5. The compound of claim 1, wherein R5 is C3-C8-cycloalkyl, C3-C8-cycloalkyl-C1-C4-alkyl or substituted or unsubstituted phenyl-C2-C4-alkyl.
6. The compound of claim 5, wherein R5 is selected from the group consisting of 2-phenethyl, cyclohexyl and cyclopentylethyl.
7. The compound of claim 1, wherein R7 is phenyl having one or more substituents independently selected from the group consisting of halogen, linear C1-C6-alkyl, branched C1-C6-alkyl, cyclic C3-C6-alkyl and trifluoromethyl.
8. The compound of claim 7, wherein R7 is phenyl having one or more substituents independently selected from the group consisting of fluoro, chloro, linear C1-C4-alkyl, and branched C1-C4-alkyl.
9. A method of treating a TNF-\u03b1 mediated condition in a patient, comprising administering to the patient a therapeutically effective amount of a compound of Formula II,
or a physiologically acceptable salt thereof, wherein,
R5 is substituted or unsubstituted aralkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted cycloalkylalkyl;
R6 is \u2014H or \u2014NR13R14;
R7 is substituted or unsubstituted phenyl; and
R13 and R14 are each, independently, \u2014H, a substituted or unsubstituted alkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl; or
R13 and R14 together with the nitrogen to which they are attached are a heterocycloalkyl.
10. The method of claim 9, wherein R5 is substituted or unsubstituted benzyl.
11. The method of claim 10, wherein R5 is benzyl having one or more substituents independently selected from the group consisting of halogen, linear C1-C4-alkoxy and branched C1-C4-alkoxy.
12. The method of claim 11, wherein R5 is benzyl having one or more substituents independently selected from the group consisting of chloro and methoxy.
13. The method of claim 9, wherein R5 is C3-C8-cycloalkyl, C3-C8-cycloalkyl-C1-C4-alkyl or substituted or unsubstituted phenyl-C2-C4-alkyl.
14. The method of claim 12, wherein R5 is selected from the group consisting of 2-phenethyl, cyclohexyl and cyclopentylethyl.
15. The method of claim 9, wherein R7 is phenyl having one or more substituents independently selected from the group consisting of halogen, linear C1-C6-alkyl, branched C1-C6-alkyl and cyclic C3-C6-alkyl and trifluoromethyl.
16. The method of claim 15, wherein R7 is phenyl having one or more substituents independently selected from the group consisting of fluoro, chloro, linear C1-C4-alkyl, and branched C1-C4-alkyl.
17. The method of claim 9, wherein the TNF-\u03b1 mediated condition is selected from the group consisting of acute and chronic immune and autoimmune pathologies.
18. The method of claim 17, wherein the TNF-\u03b1 mediated condition is selected from the group consisting of systemic lupus erythematosus, rheumatoid arthritis, thyroidosis, graft versus host disease, scleroderma, diabetes mellitus and Graves’ disease.
19. The method of claim 9, wherein the TNF-\u03b1 mediated condition is an infection.
20. The method of claim 19, wherein the TNF-\u03b1 mediated condition is selected from the group consisting of sepsis syndrome, cachexia, circulatory collapse and shock resulting from acute or chronic bacterial infection, acute and chronic parasitic, bacterial, viral and fungal infectious diseases.
21. The method of claim 9, wherein the TNF-\u03b1 mediated condition is an inflammatory disease.
22. The method of claim 21, wherein the TNF-\u03b1 mediated condition is selected from the group consisting of chronic inflammatory pathologies and vascular inflammatory pathologies.
23. The method of claim 22, wherein the TNF-\u03b1 mediated condition is selected from the group consisting of sarcoidosis, chronic inflammatory bowel disease, ulcerative colitis, Crohn’s disease, disseminated intravascular coagulation, atherosclerosis, and Kawasaki’s pathology.
24. The method of claim 9, wherein the TNF-\u03b1 mediated condition is a neurodegenerative disease.
25. The method of claim 24, wherein the TNF-\u03b1 mediated condition is selected from the group consisting of multiple sclerosis, acute transverse myelitis, lesions of the corticospinal system, disorders of the basal ganglia or cerebellar disorders, hyperkinetic movement disorders such as Huntington’s Chorea and senile chorea, drug-induced movement disorders, hypokinetic movement disorders, progressive supranucleo palsy, astructural lesions of the cerebellum, spinal ataxia, Friedreich’s ataxia, cerebellar cortical degenerations, multiple systems degenerations, Refsum’s disease, abetalipoprotemia, ataxia, telangiectasia, mitochondrial multisystem disorder, multiple sclerosis, acute transverse myelitis, neurogenic muscular atrophies, Alzheimer’s disease, Down’s Syndrome in middle age, Diffuse Lewy body disease, Senile Dementia of Lewy body type, Wernicke-Korsakoff syndrome, chronic alcoholism, Creutzfeldt-Jakob disease, Subacute sclerosing panencephalitis, Hallerrorden-Spatz disease, and Dementia pugilistica.
26. The method of claim 9, wherein the TNF-\u03b1 mediated condition is cancer.
27. The method of claim 26, wherein the TNF-\u03b1 mediated condition is selected from the group consisting of TNF-\u03b1 secreting tumors, leukemias, and lymphomas.
28. The method of claim 9, wherein the TNF-\u03b1 mediated condition is alcohol-induced hepatitis.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. An OLED comprising a flexible plastic substrate coated with multiple layers of transparent electrically conductive metal nitride separated by one or more layers of polymer, the OLED being sufficiently flexible to be processable in a web coater, wherein the OLED has a visible light transmittance of about 80-85%.
2. The OLED of claim 1, wherein the transparent electrically conductive metal nitride is selected from the group consisting of silicon nitride, aluminum nitride, and nitrides of Group IIIA and IVA elements of the Periodic Table.
3. An OLED comprising a flexible plastic substrate coated with multiple layers of transparent electrically conductive metal separated by one or more vacuum-deposited in-situ polymerized layers of polymer, wherein the OLED has a visible light transmittance of about 80-85%.
4. The OLED according to claim 3, wherein the multiple layers of transparent electrically conductive metal are in three layer configurations comprising a transparent electrically conductive oxide layer, the transparent electrically conductive metal layer, and another transparent electrically conductive oxide layer.
5. The OLED according to claim 3, wherein, the OLED does not comprise a reflective metal layer.
6. An OLED comprising a flexible substrate, at least one layer of polymer and an optically enhanced transparent conductive three layer configuration comprising adjacent layers of:
(a) electrically conductive oxide, metal, and conductive oxide;
(b) electrically conductive oxide, metal nitride, and conductive oxide;
(c) metal nitride, metal, and metal nitride; or
(d) electrically conductive oxide, metal, and metal oxide,
wherein the OLED has a visible light transmittance of about 80-85%.
7. The OLED according to claim 6, wherein the transparent electrically conductive three layer configuration comprises adjacent layers of electrically conductive oxide, electrically conductive metal nitride, and electrically conductive oxide.
8. The OLED according to claim 6, wherein the transparent electrically conductive three layer configuration comprises adjacent layers of silicon nitride, metal, and another metal nitride.
9. The OLED according to claim 6, comprising:
(a) a first transparent electrically conductive three layer configuration, and
(b) a layer of transparent electrically conductive oxide or a second transparent electrically conductive three layer configuration,
wherein (a) and (b) are separated by one or more layers of polymer.
10. The OLED according to claim 6, wherein all electrically conductive layers are electrically connected in parallel.
11. The OLED according to claim 6, further comprising an electrically conductive oxide layer of one or more of cadmium oxide, tin oxide, indium oxide, zinc oxide, gallium-containing oxide, and magnesium oxide, which oxides may be doped or undoped.
12. The OLED according to claim 6, further comprising a metal nitride layer of one or more nitride of a Group III or IV element of the Periodic Table.
13. A method for modifying a light emitting surface of an OLED, the process comprising the steps of:
(a) providing a flexible plastic substrate which optionally has a hard coat;
(b) depositing over the substrate multiple layers of transparent electrically conductive oxide that are separated by one or more layers of in-situ polymerized organic monomer; and
(c) applying the flexible plastic substrate to a light emitting surface of an OLED,
wherein the OLED has a visible light transmittance of about 80-85% after steps (a)-(c).
14. The method according to claim 13, further comprising applying a polymeric base coat to smooth the substrate prior to deposition of the transparent electrically conductive oxide.
15. The method according to claim 13, further comprising heating the substrate during or after deposition of the transparent electrically conductive oxide.
16. The method according to claim 13, further comprising depositing the transparent electrically conductive oxide in a hydrogen-containing plasma.
17. The method according to claim 13, wherein the multiple layers are deposited in a single vacuum chamber.
18. The method according to claim 13, further comprising electrically connecting all transparent electrically conductive oxide layers in parallel.
19. The method according to claim 13, further comprising contacting the transparent conductive oxide layers with a roller without causing cracking or crazing of the electrically conductive oxide layers sufficient to reduce electrical conductivity.
20. A process for fabricating an OLED, the process comprising the steps of:
(a) providing a flexible plastic substrate;
(b) depositing over the substrate a layer of in-situ polymerized organic monomer and an optically enhanced transparent electrically conductive three layer configuration comprising layers of electrically conductive oxide, metal nitride or dielectric; metal or metal nitride; and electrically conductive oxide, metal nitride or dielectric;
(c) applying the flexible plastic substrate to an OLED to obtain a visible light transmittance of about 80-85%; and optionally
(d) electrically connecting all electrically conductive layers in parallel.